Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FluBHPVE6E7 |
Synonyms | |
Therapy Description |
FluBHPVE6E7 is a cancer vaccine comprising an influenza viral vector with a C-terminal deletion of the NS1 gene and expressing HPV16 and HPV17, which potentially induces a cytotoxic T-lymphocyte (CTL) response against HPV16/17-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FluBHPVE6E7 | FluBHPVE6E7 is a cancer vaccine comprising an influenza viral vector with a C-terminal deletion of the NS1 gene and expressing HPV16 and HPV17, which potentially induces a cytotoxic T-lymphocyte (CTL) response against HPV16/17-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06589609 | Phase I | FluBHPVE6E7 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | Recruiting | AUT | 0 |